for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lumos Pharma Inc

LUMO.OQ

Latest Trade

9.14USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

7.25

 - 

36.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.14
Open
--
Volume
--
3M AVG Volume
1.20
Today's High
--
Today's Low
--
52 Week High
36.60
52 Week Low
7.25
Shares Out (MIL)
8.36
Market Cap (MIL)
75.38
Forward P/E
-2.11
Dividend (Yield %)
--

Next Event

Q3 2021 Lumos Pharma Inc Earnings Release

Latest Developments

More

Lumos Pharma Reports Second Quarter 2021 Financial Results And Provides Clinical And Corporate Updates

Lumos Pharma Reports Qtrly Loss Per Share Of $1.04

Lumos Pharma Announces Retirement Of Carl Langren And Names Lori Lawley Chief Financial Officer In Planned Succession

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lumos Pharma Inc

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.

Industry

Biotechnology & Drugs

Contact Info

4200 MARATHON BLVD., SUITE 200

AUSTIN, TX

78756

United States

+1.512.2152630

https://lumos-pharma.com/

Executive Leadership

Richard James Hawkins

Chairman of the Board, Chief Executive Officer

John C. McKew

President, Chief Operating Officer, Chief Scientific Officer

Lori D. Lawley

Chief Financial Officer, Principal Accounting Officer

Bradley J. Powers

General Counsel

David B. Karpf

Chief Medical Officer

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-12.960

2019

-10.350

2020

-0.930

2021(E)

-4.265
Price To Earnings (TTM)
--
Price To Sales (TTM)
607.93
Price To Book (MRQ)
0.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-15.14
Return on Equity (TTM)
-12.53

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up